Invex Therapeutics opens up more trial sites with second Australian ethics approval
Invex Therapeutics (ASX: IXC) has secured its second Human Research Ethics Committee (HREC) approval in Australia to begin its phase III trial evaluating its lead drug Presendin in patients with idiopathic intracranial hypertension (IIH).
New South Wales United Kingdom Alex Sinclair Clare Fraser Australian Therapeutic Goods Administration Save The Site Institute
Source: smallcaps.com.au